Caliendo G, Greco G, Grieco P, Perissutti E, Santagada V, Calignano A, Mancuso F, Novellino E
Dipartimento di Chimica Farmaceutica e Tossicologica, Università Federico II, Napoli, Italy.
Farmaco. 1996 Mar;51(3):197-201.
We report on the synthesis and the pharmacological properties of a new series of tachykinin antagonists based on the peptide N2-[(4R)-4-hydroxy-1-[(1-methyl-1H-indol-3-yl) carbonyl]-L-prolyl]-N-methyl-N-(phe-nylmethyl)-3-(2-naphthyl)-L-al aninamide (FK888) modified on the (2-naphthyl)-L-alanine and the [(1-methyl-1H-indol-3-yl)carbonyl] moieties. The compounds were tested on guinea pig ileum for NK-1, rat colon for NK-2 and rat portal vein for NK-3 receptors. The two most potent peptides of this series, 1b and 2b, were selective for the NK-2 receptor (pA2 = 7.5 and 7.3, respectively).
我们报告了基于肽N2-[(4R)-4-羟基-1-[(1-甲基-1H-吲哚-3-基)羰基]-L-脯氨酰]-N-甲基-N-(苯基甲基)-3-(2-萘基)-L-丙氨酰胺(FK888)在(2-萘基)-L-丙氨酸和[(1-甲基-1H-吲哚-3-基)羰基]部分修饰的一系列新的速激肽拮抗剂的合成及药理特性。这些化合物在豚鼠回肠上测试NK-1受体,在大鼠结肠上测试NK-2受体,在大鼠门静脉上测试NK-3受体。该系列中两种活性最强的肽1b和2b对NK-2受体具有选择性(pA2分别为7.5和7.3)。